Destiny Pharma plc
("Destiny Pharma" or "the Company")
Directorate change
Brighton, United Kingdom - 15 November 2021 - Destiny Pharma plc (AIM: DEST) a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, announces that after almost 25 years supporting the Company, Peter Morgan a Non-Executive Director, has decided to step down from the Board with effect from 31 March 2022. A search for a replacement is underway.
Nick Rodgers, Chairman of Destiny Pharma, commented:
"On behalf of Destiny Pharma, I would like to thank Peter for his considerable contribution to the Company throughout its development as a private company and the transition onto the AIM market. Destiny Pharma is now in a very exciting position to deliver significant value with two late-stage clinical programmes targeting infection prevention that have delivered strong Phase 2 clinical data and are both heading towards Phase 3 clinical studies."
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
Optimum Strategic Communications
Mary Clark / Hollie Vile / Manel Mateus
+44 (0) 208 078 4357
DestinyPharma@optimumcomms.com
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0)20 3705 9321
MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-0
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information on the company, please visit https://www.destinypharma.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
